Environmental Compliance for Medical Devices: RoHS, REACH, WEEE, and Global Regulatory Guide

Complete guide to environmental regulations for medical devices — EU RoHS restricted substances and exemptions, REACH SVHC obligations and SCIP database, WEEE producer responsibilities, global RoHS adoption in China/Korea/Saudi Arabia, and manufacturer compliance strategies in 2026.

Why Environmental Compliance Matters for Medical Devices

Medical device manufacturers operate in one of the most heavily regulated industries on earth. The focus is rightly on patient safety, clinical performance, and regulatory clearance. But there is an equally consequential layer of regulation that many device companies underestimate until it blocks a market launch or triggers an enforcement action: environmental compliance.

The European Union has built the world's most comprehensive framework of environmental product regulations. Three directives and regulations in particular create direct obligations for medical device manufacturers selling into the EU market: the RoHS Directive (restriction of hazardous substances in electrical and electronic equipment), the REACH Regulation (registration, evaluation, authorization, and restriction of chemicals), and the WEEE Directive (waste electrical and electronic equipment). None of these are optional. None can be satisfied through the medical device regulatory process alone. Each has its own scope, compliance mechanisms, and enforcement regime.

The stakes are significant. Non-compliance with environmental regulations can result in:

Market access denial -- Products that fail to meet RoHS substance restrictions cannot be placed on the EU market, regardless of their CE marking status under the MDR or IVDR
Regulatory enforcement -- National market surveillance authorities actively test products and can issue withdrawal orders, recall requirements, and fines
Customer rejection -- Hospitals, group purchasing organizations, and distributors increasingly require environmental compliance documentation as a procurement condition
Supply chain disruption -- The REACH SVHC Candidate List grows every six months, and newly listed substances can immediately affect existing products
Reputational damage -- Enforcement actions for environmental non-compliance are public and increasingly visible to healthcare procurement teams

The regulatory landscape is also in constant motion. In 2025 and 2026, the EU has adopted multiple delegated directives revising RoHS exemptions, the REACH SVHC Candidate List reached 253 entries with the February 2026 update, the European Commission has proposed repealing the SCIP database, and several countries in Asia and the Middle East have significantly expanded their own RoHS-style regulations. Medical device manufacturers need a systematic, ongoing approach to environmental compliance -- not a one-time certification exercise.

Overview of EU Environmental Regulations

Medical devices that are electrical or electronic in nature are subject to a trio of EU environmental regulations. Each addresses a different stage of the product lifecycle and imposes distinct obligations. Understanding how they overlap and interact is essential for building an efficient compliance program.

Dimension	EU RoHS (Directive 2011/65/EU)	REACH (Regulation (EC) No 1907/2006)	WEEE (Directive 2012/19/EU)
Purpose	Restrict hazardous substances in EEE	Register, evaluate, and control chemicals	Manage end-of-life waste from EEE
Scope	Electrical and electronic equipment	All chemical substances in all products	Electrical and electronic equipment
Obligation type	Substance bans (with exemptions)	Communication, notification, authorization	Producer registration, collection, recycling
Medical device scope	Most medical devices (Category 8); active implantable exempt	All products, including packaging	Medical devices (except active implantable and infected products)
Key trigger	Placing product on EU market	Presence of SVHC above 0.1% w/w	Placing EEE on EU market as producer
CE marking	Required (CE directive)	Not a CE marking regulation	Not a CE marking regulation
Enforcement	National market surveillance	National enforcement, ECHA oversight	National WEEE registers
Updates in 2025-2026	Multiple exemption revisions, new delegated directives	SVHC list at 253 entries; SCIP repeal proposed	EPR simplification under Environmental Omnibus

A critical point that many manufacturers miss: REACH applies to all products placed on the EU market, not just electrical and electronic equipment. This means REACH obligations attach to the medical device itself, its packaging, any accessories or consumables, and even standalone components. RoHS and WEEE, by contrast, apply only to equipment that depends on electric currents or electromagnetic fields to function (broadly defined).

EU RoHS Directive for Medical Devices

What RoHS Covers and How It Applies to Medical Devices

The Restriction of Hazardous Substances Directive (RoHS), formally Directive 2011/65/EU (commonly called RoHS 2), restricts the use of specific hazardous substances in electrical and electronic equipment placed on the EU market. The original RoHS Directive (2002/95/EC) did not cover medical devices. That changed with RoHS 2, which extended scope to include medical devices and monitoring/control instruments.

Medical devices were brought into scope on a phased schedule:

July 22, 2014 -- Most medical devices (Category 8, excluding active implantable) became subject to RoHS substance restrictions
July 22, 2016 -- In vitro diagnostic medical devices (Category 8, IVD subclass) became subject to RoHS
July 22, 2017 -- Industrial monitoring and control instruments (Category 9) became subject to RoHS
July 22, 2021 -- The four phthalates (DEHP, BBP, DBP, DIBP) that were added by Delegated Directive (EU) 2015/863 became enforceable for Categories 8 and 9

Active implantable medical devices remain explicitly excluded from RoHS scope under Article 2(4)(b). Equipment specifically designed for research and development (available only on a business-to-business basis) is also excluded. Batteries and packaging materials are outside RoHS scope because they are covered by separate legislation (the Batteries Regulation and Packaging and Packaging Waste Regulation, respectively).

The 10 Restricted Substances

RoHS restricts 10 substances to specified maximum concentration values (MCVs) in any homogeneous material within the product. A homogeneous material is a material of uniform composition throughout that cannot be mechanically separated into different materials -- for example, the plastic insulation on a wire, the solder on a circuit board, or the coating on a metal part.

Substance	Common Uses in Medical Devices	Maximum Concentration Value
Lead (Pb)	Solder, batteries, radiation shielding, glass/ceramic components, metal alloys	0.1% (1000 ppm)
Mercury (Hg)	Batteries, switches, lamps, measuring instruments	0.1% (1000 ppm)
Cadmium (Cd)	Batteries, pigments, coatings, stabilizers	0.01% (100 ppm)
Hexavalent chromium (Cr VI)	Surface treatments, corrosion protection, pigments	0.1% (1000 ppm)
Polybrominated biphenyls (PBB)	Flame retardants in plastic housings and components	0.1% (1000 ppm)
Polybrominated diphenyl ethers (PBDE)	Flame retardants in plastic housings and components	0.1% (1000 ppm)
Bis(2-ethylhexyl) phthalate (DEHP)	PVC plasticizer in tubing, cables, connectors	0.1% (1000 ppm)
Butyl benzyl phthalate (BBP)	PVC plasticizer	0.1% (1000 ppm)
Dibutyl phthalate (DBP)	PVC plasticizer, adhesive, ink	0.1% (1000 ppm)
Diisobutyl phthalate (DIBP)	PVC plasticizer, replacement for DBP	0.1% (1000 ppm)

The concentration limits apply to each homogeneous material, not to the entire product or component. This distinction matters enormously in practice. A printed circuit board assembly may contain dozens of homogeneous materials (individual solders, component leads, substrate laminates, conformal coatings), each of which must independently comply.

The four phthalates (DEHP, BBP, DBP, DIBP) were added to the restriction list by Delegated Directive (EU) 2015/863, sometimes informally called "RoHS 3." For medical devices and monitoring/control instruments, the phthalate restrictions became enforceable on July 22, 2021 -- two years later than for other EEE categories.

RoHS Exemptions Relevant to Medical Devices

Not all uses of restricted substances can be eliminated immediately. The RoHS Directive provides a mechanism for time-limited exemptions where substitution is scientifically or technically impracticable, or where the negative environmental or health impacts of substitution outweigh the benefits.

Exemptions specific to medical devices and monitoring/control instruments are listed in Annex IV of the Directive. Exemptions that apply broadly to all EEE categories are in Annex III. Medical device manufacturers may rely on exemptions from either annex, provided the application fits the exemption description precisely.

Key Annex IV exemptions relevant to medical devices include:

Lead in glass and ceramic components -- Widely used in X-ray shielding, radiation detection, piezoelectric sensors, and electronic ceramic components. Exemption 14 of Annex IV specifically addresses lead in glass and ceramic components of medical devices.
Cadmium in detectors -- Cadmium-based detectors remain essential for certain imaging and radiation measurement applications.
Lead in solder for specific medical applications -- High-reliability solder joints in life-supporting and life-sustaining devices.
Mercury in specific measuring instruments -- Certain analytical and diagnostic instruments still rely on mercury-containing components where no technically viable alternative exists.

The exemption system operates on the principle that exemptions are temporary. Each exemption has an expiry date, and the burden is on industry to demonstrate continued need through a renewal application. The European Commission commissions independent technical and scientific assessment studies (typically conducted by the Oeko-Institut) to evaluate whether substitution has become feasible.

Critical 2025-2026 Exemption Updates

The RoHS exemption landscape has undergone significant changes in late 2025 and early 2026, with several delegated directives published in the EU Official Journal on November 21, 2025, entering into force on December 11, 2025. These changes affect some of the most widely used exemptions across the electronics industry, including medical devices.

Exemption 6(a) -- Lead in steel: The original Exemption 6(a), covering lead as an alloying element in steel for machining purposes and in galvanized steel (up to 0.35% lead by weight), will not be renewed and expires December 11, 2026. This exemption previously applied to categories 8, 9, and 11, and now applies to all categories during its remaining validity period. No further renewal of this exemption in its current form is possible. It has been replaced by two narrower sub-exemptions: 6(a)-I (lead in steel for machining purposes, up to 0.35% by weight, expiring June 30, 2027) and 6(a)-II (lead in batch hot-dip galvanized steel, up to 0.2% by weight, expiring June 30, 2027). A renewal request was submitted in December 2025 for these sub-exemptions, which suspends their expiry pending review.

Exemption 6(b) -- Lead in aluminum: Exemption 6(b) (0.4% lead in aluminum) will not be renewed for categories 8, 9, and 11, and expires June 11, 2027. The replacement sub-exemptions introduce a significantly tightened lead cap for recycled aluminum: 6(b)-III limits lead to 0.3% by weight (down from 0.4%) for casting alloys from recycled aluminum scrap, expiring June 30, 2027 for categories 1-8, 9 (non-industrial), and 10.

Exemption 6(b)-I (recycled aluminum): For categories 1-7 and 10, this exemption expires December 11, 2026. For categories 9 (industrial) and 11, it is retained until June 30, 2027.

Exemption 6(b)-II (aluminum for machining purposes): For categories 1-7 and 10, this exemption expires June 11, 2027. For categories 9 (industrial) and 11, it is retained until June 30, 2027.

Directive (EU) 2024/232 -- Recovered PVC exemptions: This directive added a new exemption (Entry 46 of Annex III) for cadmium and lead in plastic profiles containing mixtures produced from PVC waste (recovered rigid PVC), used for electrical and electronic windows and doors. The concentration limits are 0.1% cadmium and 1.5% lead by weight in the recovered rigid PVC material. This exemption reflects the EU's effort to balance circular economy goals with substance restrictions and expires May 28, 2028.

Directive (EU) 2025/2363 -- Glass and ceramics exemptions: This directive updated exemptions related to lead in glass and ceramic components (7(c)-I and 7(c)-II), restructuring them into multiple sub-exemptions with more specific application descriptions. The renewed and new sub-exemptions expire between June 30, 2027 and December 31, 2027.

Substitution study requirement: The European Commission has mandated a new substitution study, due by the end of 2026, to assess the technical feasibility of replacing lead in various applications currently covered by exemptions. The outcome of this study will determine whether existing exemptions are renewed, narrowed, or allowed to expire.

Renewal application deadlines: For manufacturers wishing to seek renewal of exemptions expiring June 30, 2027, the deadline for submitting renewal applications was December 31, 2025. For exemptions expiring December 31, 2027, renewal applications are due by June 30, 2026. Manufacturers that miss these deadlines lose the benefit of continued validity during the review period.

RoHS Compliance Process for Medical Devices

Achieving and maintaining RoHS compliance is a multi-step process that must be integrated into the product development lifecycle.

Determine applicability -- Confirm the device falls within RoHS scope (electrical/electronic, not an excluded category such as active implantable). Assess whether any exemptions apply.
Conduct a full material declaration (FMD) analysis -- Collect material composition data from every supplier for every homogeneous material in the bill of materials (BOM). This typically requires suppliers to provide IPC 1752A declarations or equivalent material data.
Identify restricted substances -- Map each material against the 10 restricted substances. Where restricted substances are present, verify that concentrations are below the MCVs or that a valid exemption applies.
Validate exemption applicability -- For each claimed exemption, document how the specific use case matches the exemption description. Exemptions are narrow -- a general category description is not sufficient.
Conduct testing where data gaps exist -- Where supplier declarations are incomplete or unreliable, commission analytical testing from an ISO/IEC 17025 accredited laboratory using methods described in the IEC 62321 series of standards.
Prepare technical documentation -- Compile a RoHS technical file that includes material declarations, test reports, exemption justifications, and a Declaration of Conformity.
Affix CE marking -- RoHS is a CE marking directive. The device must bear the CE mark and the manufacturer must draw up an EU Declaration of Conformity covering RoHS requirements.
Monitor exemption status -- Set up a system to track exemption expiry dates and renewal decisions. When an exemption expires without renewal, the manufacturer must either reformulate the product or withdraw it from the market.

REACH Regulation for Medical Devices

What REACH Requires

The REACH Regulation (Registration, Evaluation, Authorization and Restriction of Chemicals), formally Regulation (EC) No 1907/2006, is the European Union's comprehensive chemicals management framework. Unlike RoHS, which applies only to electrical and electronic equipment, REACH applies to all chemical substances on their own, in mixtures, or in articles -- regardless of the product type. This means REACH obligations attach to medical devices, their packaging, their accessories, and any consumables or reagents supplied with them.

REACH operates through several mechanisms:

Registration -- Manufacturers and importers of chemicals must register substances they manufacture or import above one tonne per year with the European Chemicals Agency (ECHA)
Evaluation -- ECHA and member state authorities evaluate registered substances to determine risks
Authorization -- Substances of Very High Concern (SVHCs) may be placed on the Authorization List (Annex XIV), requiring companies to obtain authorization to continue using them
Restriction -- Substances may be restricted or banned from specific uses under Annex XVII

For medical device manufacturers, the most immediately relevant obligations concern SVHCs in articles.

SVHC Candidate List and Communication Obligations

The SVHC Candidate List is the mechanism by which REACH identifies substances that may have serious and often irreversible effects on human health or the environment. Once a substance is added to the Candidate List, immediate legal obligations are triggered for any company that manufactures, imports, or distributes articles containing that substance.

As of February 4, 2026, the SVHC Candidate List contains 253 entries. ECHA updates the list approximately twice per year, typically in January/February and June/July. Each update triggers new compliance obligations.

The two substances added in the February 2026 update are:

Substance	CAS Number	SVHC Classification	Common Uses
n-Hexane	110-54-3	Specific target organ toxicity after repeated exposure (Article 57(f))	Formulations, polymer processing, coatings, cleaning agents
4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (Bisphenol AF) and its salts	--	Toxicity for reproduction (Article 57(c))	Process regulators, cross-linking agents

When an SVHC is present in an article above 0.1% by weight (w/w), the following obligations apply under Article 33 of REACH:

Communication to recipients -- Suppliers of articles must provide recipients (business customers) with sufficient information to allow safe use of the article. At minimum, this must include the name of the SVHC.
Consumer right to know -- Consumers can request information about SVHCs in articles they purchase. Suppliers must respond within 45 days, free of charge, with at least the name of the substance and information enabling safe use.
ECHA notification -- Producers and importers of articles must notify ECHA if an SVHC is present above 0.1% w/w and the substance is present in quantities exceeding one tonne per producer or importer per year. This notification must be submitted within six months of the substance's addition to the Candidate List. For the February 2026 additions, the notification deadline is August 4, 2026.
Safety Data Sheet updates -- Suppliers of substances on the Candidate List (on their own or in mixtures) must update Safety Data Sheets provided to downstream users.

SCIP Database

The SCIP database (Substances of Concern In Products) was established under Article 9 of the Waste Framework Directive (Directive 2008/98/EC, as amended). It requires companies to submit notifications to ECHA when articles or complex objects they produce or import contain SVHCs above 0.1% w/w.

The SCIP database has been operational since January 2021. Unlike the REACH Article 7 notification obligation (which applies only when an SVHC exceeds one tonne per year), the SCIP obligation applies regardless of tonnage. The information submitted to SCIP is publicly accessible through ECHA's database, creating transparency about hazardous substances in products on the EU market.

Proposed repeal: On December 10, 2025, the European Commission published the Environmental Omnibus package, which includes a formal legislative proposal to amend the Waste Framework Directive and repeal the SCIP database reporting obligation. The Commission's rationale is that the administrative cost of SCIP compliance is disproportionately high, and that its functions will be better served by the upcoming Digital Product Passport (DPP) under the Ecodesign for Sustainable Products Regulation (ESPR).

Current status: As of April 2026, the SCIP reporting obligation remains in force. The legislative proposal must go through the European Parliament and Council before it takes effect. Companies must continue to submit SCIP notifications for articles containing SVHCs above 0.1% w/w. Any change is unlikely to take effect before late 2026 or 2027 at the earliest.

Practical REACH Compliance for Medical Device Manufacturers

Medical device manufacturers should take the following steps to manage REACH obligations:

Screen the full BOM against the SVHC Candidate List -- This is not a one-time exercise. Every update to the Candidate List requires a fresh screening.
Establish supplier communication protocols -- Require suppliers to provide full material declarations and to notify you of any SVHCs in their components. Include REACH compliance requirements in supplier quality agreements.
Track the Candidate List schedule -- ECHA publishes updates approximately twice per year. After each update, screen your product portfolio against the new substances within the six-month notification window.
Maintain SCIP notifications -- Continue to submit and update SCIP notifications for products containing SVHCs above 0.1% w/w, even as the potential repeal is under discussion.
Prepare for Authorization List additions -- SVHCs on the Candidate List may be moved to Annex XIV (the Authorization List). Once on Annex XIV, a substance cannot be used after a specified sunset date unless an authorization has been granted. Monitor proposed additions and prepare applications or substitution plans.
Assess product packaging -- REACH applies to packaging materials. Packaging components (plastic films, inks, adhesives, labels) may contain SVHCs and trigger independent compliance obligations.

WEEE Directive for Medical Devices

What WEEE Requires

The Waste Electrical and Electronic Equipment Directive (WEEE), formally Directive 2012/19/EU, establishes a framework for the collection, recycling, and recovery of electrical and electronic waste. It operates on the principle of Extended Producer Responsibility (EPR), meaning that producers (manufacturers, importers, and distributors who place EEE on the EU market) bear financial and operational responsibility for managing their products at end of life.

Medical devices are included in WEEE Category 8. Since August 15, 2018, the WEEE Directive has operated on an "open scope" basis, meaning all EEE is covered unless specifically excluded. For medical devices, the exclusions are:

Active implantable medical devices -- Excluded from WEEE scope
All implanted and infected products -- Excluded from WEEE collection and recycling obligations
All other medical devices that are electrical or electronic in nature are within scope

Producer Obligations

Under WEEE, a "producer" is any entity that manufactures and sells EEE under its own brand, resells equipment produced by other suppliers under its own brand, or imports or exports EEE on a professional basis into an EU member state. For non-EU manufacturers selling through importers, the importer typically bears producer obligations. However, non-EU manufacturers may also appoint an Authorized Representative to manage WEEE compliance.

The key obligations are:

Producer registration -- Every producer must register in each EU member state where they place EEE on the market. Registration is typically done through the national WEEE register. Producers must register annually and provide information on the type and quantity of equipment placed on the market.
Producer Compliance Scheme membership -- In most member states, producers placing more than 5 tonnes of EEE per year on the market must join a Producer Compliance Scheme (also called a Producer Responsibility Organization, or PRO). These schemes manage collection, recycling, and recovery on behalf of their members and handle reporting to national authorities.
Financial guarantee -- Producers must demonstrate the ability to finance the management of WEEE from their products. This is often satisfied through compliance scheme membership, but may also be demonstrated through recycling insurance, blocked bank accounts, or participation in a financing system.
Collection and recycling -- Producers are responsible for financing the collection, treatment, recovery, and environmentally sound disposal of WEEE from their products. This includes establishing or contributing to collection systems, ensuring treatment at authorized facilities, and meeting recovery and recycling targets.
Reporting -- Producers must submit periodic reports on the quantities of EEE placed on the market, collected, recycled, and recovered. Reporting formats and frequencies vary by member state.
Product design for recycling -- The Directive encourages (and increasingly requires) producers to design products that facilitate reuse, dismantling, and recovery. This includes marking plastic components with material identification codes and avoiding designs that prevent recycling.

Marking and Symbol Requirements

WEEE requires producers to mark products with the "crossed-out wheeled bin" symbol, which alerts users that the product must not be disposed of with general household waste and must be separately collected for recycling.

Important distinctions about WEEE marking:

The crossed-out wheeled bin symbol is not the same as CE marking. WEEE is not a CE marking directive.
The symbol must be printed visibly, legibly, and indelibly on the product itself. If the product is too small, the symbol may appear on the packaging, instructions for use, or warranty documentation.
A bar beneath the symbol may be added to indicate that the product was placed on the market after August 13, 2005.
Producers may also include information identifying themselves and the date on which the product was placed on the market.

Compliance Schemes and Country-by-Country Variation

WEEE is implemented through national legislation in each EU member state, meaning that registration requirements, reporting formats, fee structures, and compliance scheme options vary significantly across countries. A medical device manufacturer selling into 15 EU member states may need to register with 15 different national WEEE authorities and participate in multiple compliance schemes.

Many manufacturers address this complexity by appointing a WEEE compliance service provider or Authorized Representative who manages registrations, reporting, and compliance scheme membership across all target markets. This is particularly important for non-EU manufacturers who do not have a legal entity in each member state.

Collection targets under WEEE have been increasing. Since 2019, the minimum collection target has been 65% of the average weight of EEE placed on the market in the three preceding years, or alternatively 85% of WEEE generated on the territory of the member state. These targets continue to drive increased compliance stringency.

Global RoHS Landscape

The EU RoHS Directive has become the model for hazardous substance restrictions in electrical and electronic equipment worldwide. Numerous countries have adopted their own versions of RoHS, often closely modeled on the EU framework but with important local variations in scope, substance lists, enforcement mechanisms, and timelines. Medical device manufacturers selling globally must assess and comply with each jurisdiction's requirements independently.

China RoHS

China's "Administration on the Control of Pollution Caused by Electronic Information Products" (often called China RoHS) was one of the earliest international adopters of RoHS-style regulation. The original regulation covered a limited catalogue of products. In 2025, China published GB 26572-2025, a major update that represents a full-scale expansion of the framework, effective August 1, 2027:

Restricted substances expanded to 10 categories, aligning with EU RoHS by adding the four phthalates (DEHP, BBP, DBP, DIBP)
Stricter labeling requirements, including QR-based disclosure under the Conformity Assessment System (CAS)
Expanded scope to include accessories, connectors, and cables
A public database of restricted substance compliance information
The mandatory compliance catalogue is expected to expand from 12 to 33 products

China RoHS differs from EU RoHS in several important respects. It does not operate on an open-scope basis (products are covered only if listed in the mandatory catalogue). It includes marking and disclosure obligations that apply even when the substance restrictions are not triggered. And it requires conformity assessment through Chinese-accredited bodies.

South Korea

South Korea's Act on Resource Circulation of Electrical and Electronic Equipment and Vehicles (commonly known as Korea RoHS) has undergone significant expansion. Originally covering 10 product categories and then expanded to 26, the regulation is now undergoing a transformation:

January 1, 2026: The scope of products subject to recycling obligations (WEEE equivalent) expanded from 50 types to almost all electrical and electronic products operating at AC 1,000V or less or DC 1,500V or less. Certain exclusions apply, including medical devices with infection risks and defense products.
January 1, 2028: The scope of products subject to RoHS substance restrictions will expand from the current 50 items to most electrical and electronic products. Products that are difficult to collect or recycle will be designated as RoHS exemptions.

Korea RoHS currently restricts six substances (lead, mercury, cadmium, hexavalent chromium, PBB, PBDE), matching the original EU RoHS substance list. The four phthalates are not yet restricted under Korea RoHS. Medical devices are currently excluded from Korea RoHS scope, but manufacturers should monitor the 2028 expansion carefully, as the scope definition will move toward open scope.

Saudi Arabia (SASO RoHS)

Saudi Arabia's Standards, Metrology and Quality Organization (SASO) published its original RoHS technical regulation in January 2021, restricting six hazardous substances in specified categories of EEE. In July 2025, SASO notified the WTO of a draft Technical Regulation that would significantly overhaul the framework:

Expansion to open scope -- All electrical and electronic equipment would be subject to RoHS restrictions unless explicitly excluded. The product categories would align with Annex I of EU RoHS.
Addition of four phthalates -- DEHP, BBP, DBP, and DIBP would be added to the restricted substance list, aligning with EU RoHS.
Medical devices excluded -- The draft regulation explicitly excludes medical devices from Saudi RoHS scope, along with large-scale stationary industrial tools, large-scale fixed installations, and aerospace equipment.
Enhanced economic operator obligations -- The draft introduces detailed obligations for manufacturers, authorized representatives, importers, and distributors, modeled closely on EU RoHS.
Timeline -- The regulation enters into force 180 days after publication in the Saudi Official Gazette, with a 365-day grace period for economic operators to achieve compliance.

United Arab Emirates

The UAE adopted its RoHS regulation through the UAE Ministry of Industry and Advanced Technology, closely modeled on EU RoHS 2. It restricts the same 10 substances at the same concentration limits, covers similar product categories, and requires conformity assessment and registration. The UAE framework is generally aligned with EU RoHS in scope and substance requirements, making compliance somewhat straightforward for manufacturers already meeting EU requirements, though local registration and Arabic-language documentation requirements apply.

Turkey

Turkey's RoHS regulation is a direct transposition of EU RoHS 2 into Turkish national law, reflecting Turkey's customs union with the EU. The scope, substance restrictions, and exemption framework closely mirror the EU Directive. Medical devices are within scope on the same timeline as EU RoHS. Turkish market surveillance authorities enforce the regulation, and products must comply before being placed on the Turkish market.

Japan

Japan's approach to hazardous substances in electronics is fundamentally different from the EU model. Japan's J-MOSS (Japanese Marking for Presence of the Specific Chemical Substances) is a voluntary industry standard that requires disclosure rather than restriction. Manufacturers of covered product types (a narrower scope than EU RoHS) must label products if they contain any of six restricted substances above the specified limits, but the substances are not banned. The emphasis is on transparency and consumer information rather than substance prohibition.

Summary of Global RoHS Requirements

Country/Jurisdiction	Substances Restricted	Product Scope	Medical Devices in Scope?	Key Local Variations
EU	10 substances	Open scope (all EEE)	Yes (except active implantable)	CE marking required; Annex IV exemptions
China	Expanding to 10 (Aug 2027)	Mandatory catalogue (expanding to 33 products)	Currently no (limited catalogue)	CAS conformity assessment; QR labeling
South Korea	6 substances	Expanding to near-open scope by 2028	Currently excluded	Combined RoHS/WEEE/ELV regulation
Saudi Arabia	Expanding to 10 (pending)	Expanding to open scope (pending)	Excluded	SABER conformity assessment required
UAE	10 substances	Similar to EU RoHS	Yes	Local registration; Arabic documentation
Turkey	10 substances	Same as EU RoHS	Yes	Direct EU transposition
Japan	6 substances (disclosure only)	7 product types	Limited	Voluntary; labeling, not restriction

How Environmental Regulations Interact with Medical Device Regulations

One of the most common sources of confusion for medical device manufacturers is understanding how environmental regulations relate to medical device regulations (EU MDR 2017/745 and IVDR 2017/746). The answer is that they are parallel, independent regulatory regimes that both must be satisfied -- but they do interact in important ways.

CE Marking and Declaration of Conformity

RoHS is a CE marking directive. This means that to affix the CE mark to a medical device, the manufacturer must ensure compliance with both the MDR/IVDR and RoHS. The EU Declaration of Conformity must reference both the MDR/IVDR and RoHS as the applicable Union harmonization legislation.

WEEE and REACH are not CE marking regulations. Compliance with WEEE and REACH is legally independent of the CE marking process. However, failing to comply with WEEE or REACH can still result in market access being denied, and the obligations are enforceable regardless of whether the product bears a CE mark.

MDR/IVDR Overlap with Environmental Requirements

The EU MDR contains provisions that overlap with environmental substance requirements, particularly in Annex I (General Safety and Performance Requirements, or GSPRs):

GSPR 10.4 addresses restrictions on CMR (carcinogenic, mutagenic, reprotoxic) substances and endocrine disruptors. This includes many of the same phthalates restricted under RoHS (DEHP, DBP, BBP) and listed as SVHCs under REACH.
GSPR 10.4.1(c) requires that devices containing CMR or endocrine-disrupting substances above 0.1% w/w must identify these substances on the label.
GSPR 14.7 requires information on safe disposal of the device and any related waste, which overlaps with WEEE obligations.

This overlap creates both synergies and complications. On one hand, the material data collected for RoHS compliance (full material declarations) directly supports the substance analysis required under MDR GSPR 10.4. On the other hand, the thresholds, exemptions, and communication requirements differ between the two regulatory frameworks, and manufacturers must ensure they are meeting both sets of requirements independently.

Supply Chain Documentation

Environmental regulations create documentation requirements that complement and reinforce medical device quality system requirements. Full material declarations collected for RoHS compliance can be maintained as part of the Design History File. REACH SVHC screening data supports the risk management file required under ISO 14971. WEEE registration and compliance documentation supports the post-market surveillance infrastructure required under the MDR.

Compliance Strategy for Manufacturers

Building a sustainable environmental compliance program requires a systematic approach that is integrated into the product development lifecycle, not bolted on at the end.

Step 1: Applicability Assessment

For each product, determine which environmental regulations apply. Consider:

Is the product electrical or electronic? (RoHS and WEEE apply)
Does the product contain any chemical substances in articles? (REACH applies, regardless of whether the product is EEE)
In which markets will the product be sold? (Different RoHS regimes apply in different countries)
Does the product fall within any scope exclusions? (Active implantable devices are excluded from RoHS and WEEE)
Are any RoHS exemptions applicable to the product?

Step 2: Supply Chain Data Collection

The single most important -- and most challenging -- element of environmental compliance is obtaining accurate material composition data from suppliers. This requires:

Supplier questionnaires -- Use standardized formats (IPC 1752A, IPC 1754) to collect full material declarations from suppliers
Supplier agreements -- Include environmental compliance requirements in supplier quality agreements and purchasing contracts
Ongoing monitoring -- Suppliers change materials, formulations, and manufacturing processes without always notifying customers. Establish a cadence for re-collecting declarations (typically annually or when design changes occur)
Risk-based prioritization -- Focus initial data collection efforts on components most likely to contain restricted substances: solders, plastics (especially PVC), coatings, batteries, displays, cables, and metal alloys

Step 3: Substance Screening and Analysis

Screen all collected material data against:

The 10 RoHS restricted substances (with applicable exemptions)
The current REACH SVHC Candidate List (all 253 entries as of February 2026)
The REACH Authorization List (Annex XIV)
The REACH Restriction List (Annex XVII)
Any country-specific substance restrictions for non-EU markets

Where data gaps exist, commission analytical testing from an accredited laboratory. The IEC 62321 series of standards provides the test methods for RoHS substances. REACH SVHC screening typically requires GC-MS and ICP-MS analysis.

Step 4: Exemption Management

For medical device manufacturers relying on RoHS exemptions:

Maintain a registry of all exemptions used, including the specific product-component-application combination, the exemption number, and the expiry date
Monitor the European Commission's exemption review process (Oeko-Institut studies, Commission adoption notices, delegated directive publications)
Submit renewal applications through industry associations or directly (well in advance of the 18-month deadline)
Develop substitution plans for exemptions that are narrowing or likely to expire

Step 5: Documentation and Declaration

Prepare and maintain:

RoHS technical file -- Material declarations, test reports, exemption records, BOM-level substance analysis
EU Declaration of Conformity -- Referencing RoHS alongside MDR/IVDR
REACH communication records -- Article 33 letters to customers, responses to consumer inquiries, ECHA notifications
SCIP notifications -- Submitted to ECHA for all articles containing SVHCs above 0.1% w/w
WEEE registration certificates -- From each member state where products are placed on the market
Compliance scheme documentation -- Membership records, fee payments, annual reports

Step 6: Ongoing Monitoring

Environmental compliance is not static. The regulatory landscape changes continuously:

Track ECHA SVHC Candidate List updates (approximately twice per year)
Monitor RoHS exemption reviews and delegated directives
Watch for new global RoHS regulations or scope expansions
Review supply chain changes for compliance impact
Participate in industry associations that advocate on exemption renewals and regulatory developments

Common Compliance Mistakes

After years of helping medical device companies navigate environmental regulations, several recurring mistakes emerge:

1. Assuming CE marking under MDR covers environmental requirements. It does not. RoHS is a separate CE marking directive with its own conformity assessment requirements. REACH and WEEE are entirely independent of the CE marking process.

2. Relying on outdated supplier declarations. Suppliers frequently change materials and processes. A full material declaration collected three years ago may no longer reflect the current composition of a component. Environmental compliance data must be refreshed regularly.

3. Overlooking packaging and accessories. REACH applies to product packaging, accessories, and consumables. A medical device that is fully REACH-compliant can be rendered non-compliant by its packaging or an included accessory that contains an SVHC.

4. Misapplying RoHS exemptions. Exemptions are narrow and application-specific. A manufacturer cannot claim an exemption for "lead in solder" generically -- the exemption must precisely describe the type of solder, the application, and the equipment category. Using an Annex III exemption when an Annex IV exemption is required (or vice versa) is a compliance failure.

5. Failing to track exemption expiry dates. Exemptions have explicit expiry dates. When an exemption expires without renewal, products relying on that exemption become non-compliant overnight. This has caught manufacturers off guard repeatedly, particularly with the December 2026 and June 2027 expiry dates now approaching.

6. Treating REACH SVHC screening as a one-time exercise. The SVHC Candidate List grows every six months. A product that was compliant in January 2026 may not be compliant after the June 2026 update if a new SVHC was added that is present in the product.

7. Ignoring global RoHS requirements. A product that meets EU RoHS does not automatically comply with China RoHS, Korea RoHS, or other national variants. Each jurisdiction has its own registration, marking, and conformity assessment requirements.

8. Confusing WEEE and CE marking. The crossed-out wheeled bin is the WEEE symbol, not a CE mark. Products must display both where applicable. Conversely, WEEE compliance does not require CE marking.

9. Assuming SCIP repeal is already in effect. Despite the European Commission's proposal to repeal the SCIP database, the obligation remains legally binding until the legislation is formally adopted and enters into force. Companies that stop submitting SCIP notifications before this happens risk enforcement action.

10. Underestimating testing requirements. Supplier self-declarations alone are rarely sufficient for high-risk components. Accredited laboratory testing using standardized methods (IEC 62321 series) is necessary to validate compliance, especially for critical components like solders, coatings, and plasticized materials.

Practical Compliance Checklist

Use this checklist to assess and maintain environmental compliance for medical devices:

Regulatory Scope Assessment

Determine which environmental regulations apply (RoHS, REACH, WEEE) based on product type and target markets
Confirm product is not within any scope exclusions (active implantable, etc.)
Identify which global RoHS regimes apply in each target market

RoHS Compliance

Collect full material declarations from all suppliers (IPC 1752A format recommended)
Screen all homogeneous materials against the 10 restricted substances
Identify and document applicable exemptions with specific application descriptions
Conduct accredited laboratory testing (IEC 62321 methods) where data gaps exist
Prepare RoHS technical file and include in Declaration of Conformity
Track all exemption expiry dates and submit renewal applications by required deadlines
Monitor the December 2026 and June 2027 exemption deadlines

REACH Compliance

Screen full BOM against the current SVHC Candidate List (253 entries as of February 2026)
Assess product packaging for SVHCs
Issue Article 33 communications to customers for any SVHCs above 0.1% w/w
Submit ECHA notifications within 6 months of new SVHC additions (deadline: August 4, 2026 for February 2026 additions)
Submit SCIP notifications for articles containing SVHCs above 0.1% w/w
Update Safety Data Sheets where applicable
Monitor the SVHC Candidate List for upcoming updates (approximately June 2026)
Assess products against the Authorization List (Annex XIV) and Restriction List (Annex XVII)

WEEE Compliance

Register as a producer in each EU member state where products are placed on the market
Join a Producer Compliance Scheme (required if placing more than 5 tonnes of EEE per year)
Provide financial guarantee for WEEE management
Apply the crossed-out wheeled bin symbol to products and/or packaging
Submit periodic reports on quantities of EEE placed on the market, collected, and recycled
Appoint a WEEE Authorized Representative for markets where you have no legal entity

Supply Chain Management

Include environmental compliance requirements in supplier quality agreements
Establish a cadence for refreshing supplier material declarations
Prioritize high-risk components for testing: solders, PVC, coatings, batteries, displays, cables, metal alloys
Maintain a centralized database of material declarations linked to the product BOM

Ongoing Monitoring

Subscribe to regulatory update services or industry association notifications
Conduct quarterly reviews of exemption status for all claimed exemptions
Screen product portfolio against new SVHC Candidate List additions within the 6-month notification window
Monitor global RoHS regulatory developments (China GB 26572-2025, Korea 2028 expansion, Saudi Arabia draft regulation)
Track the SCIP repeal legislation and adjust compliance processes accordingly

Future Outlook

Environmental compliance requirements for medical devices will continue to intensify. Several major regulatory developments are on the horizon that will reshape the compliance landscape over the next three to five years.

EU Green Deal and Circular Economy

The European Green Deal, which aims to make the EU climate-neutral by 2050, is the overarching policy framework driving environmental regulation. The Circular Economy Action Plan, a core pillar of the Green Deal, specifically targets product sustainability, waste reduction, and resource efficiency. Medical devices, classified as "resource-intensive products," fall within scope.

The Circular Economy Action Plan will drive tighter substance restrictions, more ambitious recycling targets, and new requirements for product design that facilitates repair, reuse, and recycling. Manufacturers should expect RoHS substance restrictions to expand beyond the current 10 substances over time, and should begin assessing their product portfolios for substances that may be targeted in future reviews.

Corporate Sustainability Reporting Directive (CSRD)

The CSRD requires large companies (including medtech companies meeting specified thresholds) to report detailed sustainability information following the European Sustainability Reporting Standards (ESRS). ESRS E5 (Resource Use and Circular Economy) requires companies to disclose information on material resource inflows, waste generation, and circular economy practices. This reporting requirement creates a direct link between product-level environmental compliance (RoHS, REACH, WEEE) and corporate-level sustainability disclosure. Companies that lack robust environmental compliance data will struggle to meet their CSRD reporting obligations.

Digital Product Passport (DPP)

The Ecodesign for Sustainable Products Regulation (ESPR), adopted in 2024, introduces the concept of a Digital Product Passport -- a machine-readable record attached to a product that contains information about its materials, manufacturing, environmental impact, repairability, and recyclability. While medical devices have a conditional exemption under the ESPR for aspects already covered by the MDR/IVDR, the European Commission has signaled interest in extending DPP concepts to the healthcare sector. If implemented for medical devices, the DPP would consolidate much of the information currently scattered across RoHS technical files, REACH declarations, and WEEE reports into a single digital record.

The proposed repeal of the SCIP database is explicitly linked to the expectation that the DPP will provide a more effective and comprehensive solution for tracking substances of concern in products.

Potential RoHS Recast

The European Commission has been reviewing the RoHS Directive as part of its broader chemicals strategy. A potential recast could introduce:

New restricted substances (beryllium compounds, antimony trioxide, medium-chain chlorinated paraffins (MCCPs), and others have been under assessment)
Tighter exemption management processes
Better alignment with REACH substance assessments
Digital reporting requirements

Medical device industry associations, including MedTech Europe, have advocated for longer transition periods and exemption validity periods for medical devices, reflecting the long product development and regulatory approval cycles in the industry.

PFAS Restrictions

The proposed EU-wide restriction on per- and polyfluoroalkyl substances (PFAS), sometimes called the "forever chemicals" ban, is one of the most consequential chemical regulatory actions in EU history. PFAS are used in medical devices in applications including tubing, gaskets, coatings, filters, and electronic components. ECHA's committees are assessing the proposal, which could restrict thousands of PFAS across virtually all applications. Medical device manufacturers should already be assessing their exposure to PFAS and developing substitution plans.

Global Regulatory Convergence

The global trend toward adopting RoHS-style regulations is accelerating. China's GB 26572-2025 expansion, South Korea's 2028 scope expansion, and Saudi Arabia's open-scope draft regulation all reflect a convergence toward EU-style substance restriction frameworks. For medical device manufacturers, this means that compliance investments made for the EU market increasingly provide a foundation for compliance in other markets -- but local registration, testing, and documentation requirements still need to be addressed jurisdiction by jurisdiction.

The direction is clear: environmental compliance is becoming more comprehensive, more stringent, and more globally harmonized. Medical device manufacturers that build robust compliance infrastructure now will be better positioned to adapt to these changes as they unfold. Those that treat environmental compliance as an afterthought will face increasing regulatory risk, market access barriers, and competitive disadvantage.